olivLaw · US equity research
Absci Corporation ABSI
Services-Commercial Physical & Biological Research · SIC 8731 · Vertical: Services-Commercial Physical & Biological Research (SIC 8731)
Absci is a clinical-stage biopharmaceutical company that uses generative AI to design therapeutic antibodies, built around its Integrated Drug Creation platform and the Origin-1 model. The current focus is ABS-201, an anti-PRLR antibody tested for androgenetic alopecia and endometriosis, with interim Phase 1 data reported in June 2026. The company remains loss-making, and its revenue comes from partner collaborations rather than product sales.
At the close of 04 Nov 2026, Absci Corporation (ABSI) stock was 10.48 USD (+4.80% on the day), with market capitalisation 1.8 bn USD, beta 2.55, 52-week range 2.30–12.10 USD. Latest reported quarter (Q2 2026): revenue of 318.0 k USD (−46.4% YoY), net income of -33.2 m USD, diluted EPS -0.21 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 53.3
- neutral
- Bollinger (20, 2)
- 7.71 – 11.82
- in the upper half of the band · %B 0.67 · band width 42.1%
- SMA 50 / 200
- 9.55 / 6.60
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.29 / 0.23
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −9.1% | −1.1% | −8.0 pp | — |
| 3 months | +24.8% | −0.5% | +25.2 pp | — |
| 6 months | +76.1% | +4.4% | +71.7 pp | — |
| Year to date | +200.3% | +12.3% | +188.0 pp | — |
| 1 year | +166.0% | +13.5% | +152.4 pp | +10.9% |
| 3 years | +638.0% | +76.4% | +561.6 pp | −23.9% |
| 5 years | −37.9% | +63.7% | −101.6 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.7 m | 665.0 k | 1.2 m | 593.0 k | 378.0 k | 650.0 k | 215.0 k | 318.0 k |
| Research & development | 18.0 m | 18.4 m | 16.4 m | 20.5 m | 19.2 m | 25.3 m | 19.3 m | 22.6 m |
| SG&A | 9.3 m | 8.8 m | 9.5 m | 8.5 m | 8.4 m | 8.6 m | 9.1 m | 9.2 m |
| Operating income | -28.9 m | -29.8 m | -27.7 m | -31.4 m | -30.2 m | -31.0 m | -30.8 m | -34.2 m |
| Depreciation & amortisation | 3.4 m | 3.2 m | 3.1 m | 3.0 m | 2.8 m | 2.8 m | 2.7 m | 2.7 m |
| Interest expense | 130.0 k | 109.0 k | 79.0 k | 56.0 k | 45.0 k | 29.0 k | 18.0 k | 2.0 k |
| Pre-tax income | -27.4 m | -29.0 m | -26.4 m | -30.4 m | -28.6 m | -29.7 m | -29.6 m | -33.2 m |
| Income tax | 37.0 k | 21.0 k | -4.0 k | 131.0 k | 104.0 k | -162.0 k | 18.0 k | 40.0 k |
| Net income | -27.4 m | -29.0 m | -26.3 m | -30.6 m | -28.7 m | -29.6 m | -29.6 m | -33.2 m |
| Diluted EPS | -0.24 | -0.25 ≈ | -0.21 | -0.24 | -0.20 | -0.20 ≈ | -0.19 | -0.21 |
| Operating cash flow | -20.7 m ≈ | -17.0 m | -21.8 m | -16.9 m ≈ | -25.0 m ≈ | -29.2 m | -26.3 m | -27.6 m ≈ |
| Capex | 48.0 k ≈ | 23.0 k | 25.0 k | 223.0 k ≈ | 962.0 k ≈ | -103.0 k | 30.0 k | 1.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 4.8 m | 4.8 m | 5.7 m | 5.7 m | 4.5 m | 2.8 m |
| Revenue YoY | unavailable | +0.0% | +20.2% | −0.5% | −20.7% | −38.2% |
| Net income | -14.4 m | -101.0 m | -104.9 m | -110.6 m | -103.1 m | -115.2 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -3.19 | -2.08 | -1.15 | -1.20 | -0.94 | -0.84 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -300.3% | -2,111.3% | -1,825.4% | -1,933.6% | -2,274.1% | -4,113.7% |
| Free cash flow | -13.2 m | -98.6 m | -97.5 m | -65.5 m | -72.8 m | -94.0 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 20.0 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 189.4 m USD
- Total assets
- 216.3 m USD
- Debt / equity
- unavailable
- Current ratio
- 6.57x
- ROE
- -62.5%
- ROA
- -53.6%
- FCF margin
- -3,358.3%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 4.8 m | 4.8 m | 5.7 m | 5.7 m | 4.5 m | 2.8 m | SEC (XBRL)· 24 Mar 2026verified |
| Research & development | 11.4 m | 44.6 m | 58.9 m | 48.1 m | 63.9 m | 81.4 m | SEC (XBRL)· 24 Mar 2026verified |
| SG&A | 5.5 m | 28.8 m | 40.6 m | 37.8 m | 36.2 m | 35.1 m | SEC (XBRL)· 24 Mar 2026verified |
| Operating income | -13.3 m | -75.2 m | -106.8 m | -115.5 m | -108.9 m | -120.3 m | SEC (XBRL)· 24 Mar 2026verified |
| Depreciation & amortisation | 1.1 m | 6.7 m | 13.0 m | 14.0 m | 13.4 m | 11.7 m | SEC (XBRL)· 24 Mar 2026verified |
| EBITDA | -12.2 m ≈ | -68.6 m ≈ | -93.7 m ≈ | -101.5 m ≈ | -95.5 m ≈ | -108.6 m ≈ | SEC (XBRL)· 24 Mar 2026derived |
| Interest expense | 634.0 k | 3.4 m | 972.0 k | 1.0 m | 565.0 k | 209.0 k | SEC (XBRL)· 24 Mar 2026verified |
| Pre-tax income | -14.4 m | -109.9 m | -105.4 m | -110.5 m | -103.0 m | -115.1 m | SEC (XBRL)· 24 Mar 2026verified |
| Income tax | 0 | -8.9 m | -461.0 k | 100.0 k | 70.0 k | 69.0 k | SEC (XBRL)· 24 Mar 2026verified |
| Net income | -14.4 m | -101.0 m | -104.9 m | -110.6 m | -103.1 m | -115.2 m | SEC (XBRL)· 24 Mar 2026verified |
| Diluted EPS | -3.19 | -2.08 | -1.15 | -1.20 | -0.94 | -0.84 | SEC (XBRL)· 24 Mar 2026verified |
| Weighted average diluted shares | 15.5 m | 49.7 m | 90.8 m | 92.0 m | 110.2 m | 136.8 m | SEC (XBRL)· 24 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 69.9 m | 252.6 m | 60.0 m | 72.4 m | 41.2 m | 20.0 m | SEC (XBRL)· 24 Mar 2026verified |
| Receivables | — | — | — | 2.2 m | 0 | — | SEC (XBRL)· 18 Mar 2025verified |
| Current assets | 73.2 m | 273.1 m | 186.9 m | 120.6 m | 133.8 m | 149.6 m | SEC (XBRL)· 24 Mar 2026verified |
| Goodwill | 0 | 21.3 m | 21.3 m | 0 | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Intangibles (excl. goodwill) | 0 | 55.0 m | 51.6 m | 48.3 m | 44.9 m | 41.5 m | SEC (XBRL)· 24 Mar 2026verified |
| Total assets | 88.6 m | 426.2 m | 321.0 m | 217.3 m | 213.6 m | 216.3 m | SEC (XBRL)· 24 Mar 2026verified |
| Accounts payable | 2.1 m | 8.4 m | 2.4 m | 1.5 m | 2.9 m | 2.8 m | SEC (XBRL)· 24 Mar 2026verified |
| Long-term debt | — | 3.5 m | 10.9 m | 7.9 m | 4.0 m | — | SEC (XBRL)· 18 Mar 2025verified |
| Current liabilities | 10.1 m | 33.9 m | 30.3 m | 29.6 m | 28.7 m | 22.8 m | SEC (XBRL)· 24 Mar 2026verified |
| Total liabilities | 21.6 m | 60.1 m | 46.6 m | 41.1 m | 34.5 m | 26.8 m | SEC (XBRL)· 24 Mar 2026verified |
| Equity | -89.4 m † | 366.1 m † | 274.4 m † | 176.2 m † | 179.1 m † | 189.4 m † | SEC (XBRL)· 24 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -11.0 m | -60.6 m | -81.3 m | -64.6 m | -72.4 m | -92.9 m | SEC (XBRL)· 24 Mar 2026verified |
| Capex | 2.2 m | 38.0 m | 16.2 m | 860.0 k | 404.0 k | 1.1 m | SEC (XBRL)· 24 Mar 2026verified |
| Free cash flow | -13.2 m ≈ | -98.6 m ≈ | -97.5 m ≈ | -65.5 m ≈ | -72.8 m ≈ | -94.0 m ≈ | SEC (XBRL)· 24 Mar 2026derived |
| Investing cash flow | -2.2 m | -67.4 m | -127.0 m | 81.9 m | -41.6 m | -50.2 m | SEC (XBRL)· 24 Mar 2026verified |
| Financing cash flow | 71.0 m | 336.2 m | 5.2 m | -4.5 m | 82.5 m | 105.9 m | SEC (XBRL)· 24 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 1.8 bn USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -7,756.4% | 0 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | -21.3% | 0 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -1,342.5x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 10.6x | 100 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -6.1% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet40/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ABSCI CORP (ABSI). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 2.8 m USD in 2025; YoY growth -38.2%; net margin -7,756.4%; ROE -57.7%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 10.6x
What contradicts it
- Net margin: -7,756.4%
- Revenue CAGR 3Y: -21.3%
- Interest coverage: -1,342.5x
- FCF yield: -6.1%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Services-Commercial Physical & Biological Research (SIC 8731) · same industry (4-digit SIC) · compared with 11 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| IQVIqvia Holdings Inc. | 43.5 bn | 32.0 | 21.7% | 8.1% | +5.9% | +15% / +23% |
| INCYIncyte Corporation | 25.0 bn | 65.2 | 7.8% | 6.7% | +21.2% | +18% / +126% |
| MEDPMedpace Holdings, Inc. | 18.4 bn | 36.4 | 117.9% | 18.2% | +20.0% | +11% / +143% |
| CRLCharles River Laboratories International, Inc. | 15.6 bn | 385.5 | 1.2% | 1.0% | −0.9% | +83% / +66% |
| ICLRICON plc | 15.6 bn | 70.0 | 2.5% | 2.8% | +0.8% | +10% / −24% |
| ABSIAbsci Corp | 1.8 bn | — | -57.7% | -7,756.4% | −38.2% | +166% / +638% |
| OABIOmniab, Inc. | 755.6 m | — | -16.5% | -108.1% | −29.3% | +186% / +18% |
| NRCNRC Health | 574.5 m | 95.9 | 248.1% | 4.5% | −4.0% | +59% / −35% |
| ONMDOnemednet Corporation | 269.2 m | — | — | -584.2% | +111.4% | −75% / −89% |
| MXCTMaxCyte, Inc. | 143.5 m | — | -20.4% | -114.8% | −14.5% | −21% / −71% |
| BIAFbioAffinity Technologies, Inc. | 23.7 m | — | -1,860.2% | -257.3% | −34.2% | −87% / −100% |
| ISPCiSpecimen Inc. | 2.1 m | — | -968.5% | -2,449.0% | −79.2% | −95% / −100% |
1- and 3-year price returns: for ABSI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Absci is a clinical-stage biopharmaceutical company that uses generative AI to design therapeutic antibodies, built around its Integrated Drug Creation platform and the Origin-1 model. The current focus is ABS-201, an anti-PRLR antibody tested for androgenetic alopecia and endometriosis, with interim Phase 1 data reported in June 2026. The company remains loss-making, and its revenue comes from partner collaborations rather than product sales.
SWOT
Strengths
- An integrated platform combining generative models with rapid laboratory validation and internally generated proprietary data.
- A lead program, ABS-201, with interim Phase 1 data considered favourable on safety and half-life.
- Backing from strategic investors and established pharmaceutical companies, including a recent investment from Eli Lilly.
Weaknesses
- Revenue is small and depends on milestone timing in collaborations, with no royalties yet.
- Net losses are persistent, and accumulated losses have reached high levels.
- No product is approved, and the company has not yet demonstrated the ability to complete large clinical studies.
Opportunities
- If efficacy data from the Phase 1/2a program are confirmed, ABS-201 could open a new treatment category for hair loss.
- Expanding the program into endometriosis could add a very large market where no disease-modifying therapy exists yet.
- Licensing internal programs to partners could bring non-dilutive capital and recurring revenue.
Threats
- Clinical risks are high, and Phase 1 results do not guarantee success in efficacy studies.
- The need for capital could lead to shareholder dilution or restrictive terms from financiers.
- Competition for partnerships and for investor attention in AI-driven medicine is intense.
Risks
- Dependence on ABS-201high
Much of the company's value rests on a single clinical program, and a failure in efficacy studies could affect the whole pipeline.
- Need for additional fundinghigh
The company has said it will need additional capital to fund clinical development, which could lead to dilution.
- Irregular revenuemedium
Collaboration revenue depends on milestone timing and partner decisions, so results fluctuate from period to period.
- No commercial licences yetmedium
No partner has yet entered a licence for clinical or commercial use, which could delay meaningful revenue 1.
- Loss historylow
The company has not yet reached profitability and has a short operating history, which makes long-term viability hard to assess 1.
Investment thesis
What would need to be true (bull case)
- If efficacy data from HEADLINE confirm what was seen in Phase 1, ABS-201 could become the first durable treatment for hair loss and open a new category.
- The strategic investment from a large pharmaceutical company and the recent financing could ease near-term capital pressure and help validate the platform.
- Expansion into endometriosis could add a large market without an approved disease-modifying therapy, using a non-hormonal mechanism.
What would break the thesis
- Most programs are still preclinical or in early clinical stages, and industry history shows many molecules never reach approval.
- Persistent net losses and small revenue could force further share issuances, diluting shareholders.
- If partners do not move to commercial licences, the collaboration-based model could keep revenue unstable and small.
What to watch
- Interim efficacy data for ABS-201 in hair losssecond half of 2026
- Full efficacy data from the HEADLINE studyearly 2027
- Start of the Phase 2 endometriosis trialQ4 2026
- Cash position and funding need against the company's guidance of funding into the second half of 2028Q3 2026 and next 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Absci develops therapeutic antibodies through a lab-in-a-loop, a continuous cycle between AI models and wet-lab validation that the company says can take a design to validation in as little as six weeks. All revenue in fiscal 2025 came from drug creation work for partnered programs, and no partner has yet licensed clinical or commercial use of its intellectual property 1. The internal pipeline includes five wholly-owned programs, of which ABS-201 and ABS-202 are the most advanced 12.
The headquarters and primary research facilities are in Vancouver, Washington, with AI research labs in New York and Belgrade and an innovation center in Zug, Switzerland 2. The company has a strategic collaboration with AMD to optimise AMD Instinct accelerators for its antibody design models 1.
The business model combines internally developed programs that may be advanced to commercialisation or partnered, drug creation collaborations with pharmaceutical companies, and co-development partnerships 1. Past partners include Merck, AstraZeneca and Almirall, according to the annual report 1.
Segments
Partnerships and licensing
The company announced a new partnership with Eli Lilly tailored to the clinical strategy for ABS-201, which does not confer program rights on Eli Lilly 3. This segment could become a revenue source if partners move to commercial licences, but that has not yet happened.
Market context
The company states that androgenetic alopecia affects approximately 80 million people in the United States alone, and that no approved therapy provides durable hair regrowth 2. Endometriosis is prevalent in up to 10% of women worldwide, and there is still no FDA-approved disease-modifying therapy for it 3. Companies in therapeutic antibodies and AI-driven design compete both for these patients and for partnerships with pharmaceutical companies.
The company describes the treatment landscape for these conditions as unmet, which could make a new treatment a distinct therapeutic category if clinical data confirm efficacy 1. The company has not provided market size estimates, so commercial projections remain speculative at this stage.
Trends
- AI in drug discoverytailwind
The US drug regulator acknowledged in 2023 the potential role of AI in drug development, and industry players argue generative design can shorten the time to clinic 1. If this promise holds clinically, it could support the value of the Absci platform.
- Strategic interest from large pharmamixed
Eli Lilly's 40 million USD investment signals strategic interest in the ABS-201 program 3. Such partnerships can strengthen funding, but may also limit the company's rights over its programs.
- Shift from research to clinical operationsmixed
The company has stated it will need to move from a research-focused organisation to one able to support commercial activities, and this transition is uncertain 1. If successful, it could change the company's risk profile.
Competitive position
Absci competes with other companies developing therapeutic antibodies and AI-assisted design platforms, though the available sources do not allow every direct competitor in each indication to be identified with certainty. The company emphasises focusing on underexplored mechanisms where competition is low 1.
The company's stated advantage lies in the cost and speed of reaching IND compared with industry averages, along with proprietary lab data used to train its models 1. Such an advantage could matter more if the platform also produces clinical results.
- Eli Lilly & CompanyLLY
Pharmaceutical company that invested 40 million USD in Absci and entered a partnership tied to ABS-201, making it more a partner than a direct competitor.
- Advanced Micro DevicesAMD
Supplier of compute accelerators with which the company has a collaboration to optimise its antibody design models, relevant mainly as a technology partner.
- MerckMRK
Former partner in drug creation projects, illustrating competition for the attention of large pharmaceutical companies.
- AstraZenecaAZN
Former partner that shows large pharmaceutical companies can explore several AI platforms in parallel.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
- Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as OzempicYahoo Finance — News · 12 Sept 2026 · EN
SEC filings
- Quarterly report11 Aug 2026
- Current report11 Aug 2026Results of operations · Other events · Financial statements and exhibits
- Current report24 Jun 2026Material agreement · Other events · Financial statements and exhibits
- Current report24 Jun 2026Other events
- Current report05 Jun 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Other events · Financial statements and exhibits
- Proxy statement22 Apr 2026
- Annual report24 Mar 2026
- Current report24 Mar 2026Results of operations · Other events · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Absci Corporation · 24 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Absci Corporation · 11 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Absci Corporation · 11 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.